Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Xi, Heming
TQB2450-II-13, NCT05013697: TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.	Not yet recruiting	2	48	RoW	Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib, Paclitaxel + Cisplatin + TQB2450 injection	Henan Cancer Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Esophageal Neoplasms	12/22	07/23